



# ASBM Study: US Physician Perspectives on Interchangeable Biosimilars

ISR Market Research

[www.ISRreports.com](http://www.ISRreports.com)

August 2024



# Table of Contents

|    |                         |
|----|-------------------------|
| 3  | Objective & Methodology |
| 7  | Respondent Profile      |
| 11 | Findings                |
| 22 | About ISR               |



# Objective & Methodology



## Objective

Understand US prescribers' attitudes and beliefs regarding the interchangeability of biosimilar medications with the originator biologics and the need for specific evaluation for the impact of switching on safety and efficacy.



# Methodology

- On behalf of Alliance for Safe Biologic Medicines (ASBM), ISR Market Research conducted a web-based quantitative survey with 270 participants
- All participants practice medicine in the United States
  - 9 practice areas were included: Dermatology, Endocrinology, Gastrointestinal, Immunology, Nephrology, Neurology, Oncology, Ophthalmology, and Rheumatology
- A leading 3<sup>rd</sup> party physician panel was used to recruit research participants
- Research was conducted in August 2024
- ASBM was not identified as the sponsor of the research
- Participants were provided an honorarium for their time

## Explanatory Text

- Respondents were shown the below explanatory text about biosimilars prior to receiving the survey questions.

***“This survey will focus on the interchangeability of biosimilars. Please carefully read the description below to understand the latest legislation on this issue. The button to continue will appear after a few seconds.***

*BIOSIMILARS are copies of previously approved biologic medicines. Biologics, including biosimilars, are often used to treat serious and chronic conditions including rheumatoid arthritis, psoriasis, Crohn’s disease, and cancer.*

*Biosimilars are safe and effective, however, unlike traditional chemical drugs, copies of biologics are highly similar but not identical to the medicines they copy because all biologics are made using living cells and the cell lines and the manufacturing process are proprietary.*

*Unlike generic drugs, biosimilars as a class may not be substituted at the pharmacy-level without involvement of the prescriber. However, all 50 states have passed laws permitting “INTERCHANGEABLE BIOSIMILARS” to be substituted at the pharmacy level.*

*In order for a biologic to be designated as “Interchangeable”, additional data is submitted to the FDA demonstrating that a patient who is switched from the reference product to the biosimilar will experience no loss of safety or efficacy, even over multiple switches, relative to a patient who was not switched, so as to ensure a patient’s treatment stability is not jeopardized by a third-party non-medical switch. The FDA currently has broad flexibility to determine what data is required to demonstrate this; it may or may not require switching studies to be conducted prior to designation as interchangeable.*

*Congress is currently considering legislation which would require FDA to deem ALL biosimilars interchangeable (that is, make all biosimilars substitutable at the pharmacy level by a third-party insurer/PBM without physician involvement, like generics) and lower the approval standards by preventing the FDA from considering switching studies during approval. The FDA is also currently seeking comment on a proposal to eliminate its ability to consider switching studies when making a determination of interchangeability.”*



# Respondent Profile

# Respondent Profile




## US State Representation

| State                | n  | State         | n  | State          | n  | State          | n  |
|----------------------|----|---------------|----|----------------|----|----------------|----|
| Alabama              | 1  | Illinois      | 18 | Montana        | 0  | Rhode Island   | 1  |
| Alaska               | 0  | Indiana       | 8  | Nebraska       | 1  | South Carolina | 4  |
| Arizona              | 7  | Iowa          | 2  | Nevada         | 2  | South Dakota   | 0  |
| Arkansas             | 2  | Kansas        | 2  | New Hampshire  | 1  | Tennessee      | 1  |
| California           | 44 | Kentucky      | 2  | New Jersey     | 9  | Texas          | 25 |
| Colorado             | 3  | Louisiana     | 3  | New Mexico     | 2  | Utah           | 1  |
| Connecticut          | 2  | Maine         | 0  | New York       | 24 | Vermont        | 0  |
| Delaware             | 0  | Maryland      | 5  | North Carolina | 6  | Virginia       | 4  |
| District of Columbia | 1  | Massachusetts | 12 | North Dakota   | 0  | Washington     | 8  |
| Florida              | 14 | Michigan      | 4  | Ohio           | 10 | West Virginia  | 1  |
| Georgia              | 9  | Minnesota     | 4  | Oklahoma       | 1  | Wisconsin      | 2  |
| Hawaii               | 2  | Mississippi   | 1  | Oregon         | 4  | Wyoming        | 0  |
| Idaho                | 0  | Missouri      | 4  | Pennsylvania   | 13 |                |    |



## Practice Type








# Respondent Profile




| Therapeutic Specialty | n  |
|-----------------------|----|
| Dermatology           | 30 |
| Endocrinology         | 30 |
| Gastrointestinal      | 30 |
| Immunology            | 30 |
| Nephrology            | 30 |
| Neurology             | 30 |
| Oncology              | 30 |
| Ophthalmology         | 30 |
| Rheumatology          | 30 |





# Respondent Profile






# Findings



# Comfort with Switching if Biosimilar Has Been Specifically Evaluated

Q1. To what extent do you agree with the following statement: “I am more comfortable switching a patient from an originator biologic to a biosimilar if that medicine has been specifically evaluated for the impact of switching on safety and efficacy.” (n=270)



- 87% of respondents agreed that they are more comfortable switching a patient from an originator biologic to a biosimilar if that medicine has been specifically evaluated for the impact of switching on safety and efficacy.



# Comfort with Switching if Biosimilar Has Been Specifically Evaluated – by Therapeutic Specialty

Q1. To what extent do you agree with the following statement: “I am more comfortable switching a patient from an originator biologic to a biosimilar if that medicine has been specifically evaluated for the impact of switching on safety and efficacy.”


|                            | Total | Dermatology | Endocrinology | Gastrointestinal | Immunology           | Nephrology | Neurology   | Oncology    | Ophthalmology | Rheumatology |
|----------------------------|-------|-------------|---------------|------------------|----------------------|------------|-------------|-------------|---------------|--------------|
| n-size                     | 270   | 30          | 30            | 30               | 30                   | 30         | 30          | 30          | 30            | 30           |
|                            |       | A           | B             | C                | D                    | E          | F           | G           | H             | I            |
| Strongly agree             | 53%   | 40%         | 67%<br>A, F   | 60%              | 57%                  | 50%        | 37%         | 50%         | 67%<br>A, F   | 53%          |
| Slightly agree             | 34%   | 37%         | 30%           | 30%              | 17%                  | 37%        | 53%<br>D, H | 47%<br>D, H | 20%           | 33%          |
| Neither agree nor disagree | 5%    | 3%          | 0%            | 10%              | 13%<br>B, H          | 3%         | 7%          | 3%          | 0%            | 3%           |
| Slightly disagree          | 3%    | 10%         | 3%            | 0%               | 0%                   | 0%         | 3%          | 0%          | 3%            | 10%          |
| Strongly disagree          | 4%    | 7%          | 0%            | 0%               | 13%<br>B, C, F, G, I | 7%         | 0%          | 0%          | 7%            | 0%           |
| Unsure                     | 1%    | 3%          | 0%            | 0%               | 0%                   | 3%         | 0%          | 0%          | 3%            | 0%           |

Note: A capital letter under the % means that the number in that cell is significantly larger than the number in the cell indicated by the capital letter. For example, a significantly higher percentage of Endocrinology and Ophthalmology specialists (columns B and H) selected “Strongly agree” than Dermatology and Neurology Specialists (columns A and F).



# Whether Interchangeable Biosimilars Should Be Individually Evaluated

Q2. "Which of the following statements best represents your opinion on deeming biosimilars as interchangeable with the original biologic product?" (n=270)



- 88% of respondents believe each interchangeable biosimilar should be individually evaluated specifically for the impact of switching on safety and efficacy.
- Only 11% believe all biosimilars should be deemed interchangeable.

Note: The words each and all were underlined in the response options when respondents took the survey.

# Whether Interchangeable Biosimilars Should Be Individually Evaluated – by Therapeutic Specialty


Q2. “Which of the following statements best represents your opinion on deeming biosimilars as interchangeable with the original biologic product:” (n=270)

|  | Total | Dermatology | Endocrinology | Gastrointestinal | Immunology | Nephrology | Neurology | Oncology | Ophthalmology  | Rheumatology |
|--|-------|-------------|---------------|------------------|------------|------------|-----------|----------|----------------|--------------|
| n-size   | 270   | 30          | 30            | 30               | 30         | 30         | 30        | 30       | 30             | 30           |
|  |       | A           | B             | C                | D          | E          | F         | G        | H              | I            |
| I strongly believe <u>each</u> interchangeable biosimilar should be individually evaluated specifically for the impact of switching on safety and efficacy | 55%   | 53%         | 53%           | 57%              | 63%<br>F   | 63%<br>F   | 33%       | 50%      | 77%<br>F, G, I | 43%          |
| I somewhat believe <u>each</u> interchangeable biosimilar should be individually evaluated specifically for the impact of switching on safety and efficacy | 33%   | 40%         | 30%           | 30%              | 27%        | 30%        | 47%       | 33%      | 23%            | 37%          |
| I somewhat believe <u>all</u> biosimilars should be deemed interchangeable   | 10%   | 3%          | 13%<br>H      | 10%              | 10%        | 7%         | 17%<br>H  | 17%<br>H | 0%             | 17%<br>H     |
| I strongly believe <u>all</u> biosimilars should be deemed interchangeable   | 0%    | 0%          | 3%            | 0%               | 0%         | 0%         | 0%        | 0%       | 0%             | 0%           |
| Unsure/No opinion  | 1%    | 3%          | 0%            | 3%               | 0%         | 0%         | 3%        | 0%       | 0%             | 3%           |



# Whether Only Individually Evaluated Biosimilars Should Be Deemed Interchangeable

Q3. To what extent do you agree with the following statement: "Only biosimilars that have been individually evaluated specifically for the impact of switching on safety and efficacy should be deemed interchangeable." (n=270)



- 85% of respondents agreed that only biosimilars that have been individually evaluated specifically for the impact of switching on safety and efficacy should be deemed interchangeable.





# Whether Only Individually Evaluated Biosimilars Should Be Deemed Interchangeable – by Therapeutic Specialty


Q3. To what extent do you agree with the following statement: “Only biosimilars that have been individually evaluated specifically for the impact of switching on safety and efficacy should be deemed interchangeable.” (n=270)

|                            | Total | Dermatology | Endocrinology | Gastrointestinal | Immunology | Nephrology  | Neurology   | Oncology | Ophthalmology | Rheumatology |
|----------------------------|-------|-------------|---------------|------------------|------------|-------------|-------------|----------|---------------|--------------|
| n-size                     | 270   | 30          | 30            | 30               | 30         | 30          | 30          | 30       | 30            | 30           |
|                            |       | A           | B             | C                | D          | E           | F           | G        | H             | I            |
| Strongly agree             | 54%   | 57%         | 70%<br>G      | 47%              | 57%        | 47%         | 50%         | 43%      | 60%           | 60%          |
| Slightly agree             | 31%   | 30%         | 17%           | 33%              | 43%<br>B   | 23%         | 27%         | 40%<br>B | 37%           | 27%          |
| Neither agree nor disagree | 9%    | 10%         | 7%            | 17%<br>D, H      | 0%         | 13%<br>D, H | 13%<br>D, H | 10%      | 0%            | 10%          |
| Slightly disagree          | 4%    | 0%          | 7%            | 0%               | 0%         | 10%         | 10%         | 7%       | 3%            | 3%           |
| Strongly disagree          | 0%    | 0%          | 0%            | 0%               | 0%         | 3%          | 0%          | 0%       | 0%            | 0%           |
| Unsure                     | 1%    | 3%          | 0%            | 3%               | 0%         | 3%          | 0%          | 0%       | 0%            | 0%           |



# Biosimilar Switching Studies' Effects on Confidence in Safety

Q4. To what extent do you agree with the following statement: "Biologics are complex medicines that can cause unwanted immune responses in patients; biosimilar switching studies **increase my confidence** in the safety of moving my patients from an originator medicine to the biosimilar that has been studied and determined to be interchangeable with the originator." (n=270)



- 88% of respondents agreed that biosimilar switching studies increase their confidence in the safety of moving their patients from an originator medicine to the biosimilar that has been studied and determined to be interchangeable with the originator.

# Biosimilar Switching Studies' Effects on Confidence in Safety – by Therapeutic Specialty

Q4. To what extent do you agree with the following statement: “Biologics are complex medicines that can cause unwanted immune responses in patients; biosimilar switching studies **increase my confidence** in the safety of moving my patients from an originator medicine to the biosimilar that has been studied and determined to be interchangeable with the originator.” (n=270)

|                            | Total | Dermatology | Endocrinology | Gastrointestinal | Immunology | Nephrology | Neurology | Oncology | Ophthalmology     | Rheumatology |
|----------------------------|-------|-------------|---------------|------------------|------------|------------|-----------|----------|-------------------|--------------|
| n-size                     | 270   | 30          | 30            | 30               | 30         | 30         | 30        | 30       | 30                | 30           |
|                            |       | A           | B             | C                | D          | E          | F         | G        | H                 | I            |
| Strongly agree             | 47%   | 37%         | 50%           | 47%              | 57%        | 33%        | 40%       | 50%      | 70%<br>A, E, F, I | 40%          |
| Slightly agree             | 41%   | 53%<br>H    | 40%           | 37%              | 33%        | 47%        | 50%       | 33%      | 27%               | 53%<br>H     |
| Neither agree nor disagree | 7%    | 7%          | 3%            | 17%              | 7%         | 10%        | 10%       | 7%       | 3%                | 3%           |
| Slightly disagree          | 2%    | 0%          | 7%            | 0%               | 0%         | 7%         | 0%        | 7%       | 0%                | 0%           |
| Strongly disagree          | 1%    | 0%          | 0%            | 0%               | 3%         | 0%         | 0%        | 0%       | 0%                | 3%           |
| Unsure                     | 1%    | 3%          | 0%            | 0%               | 0%         | 3%         | 0%        | 3%       | 0%                | 0%           |

## Industry-leading Syndicated & Custom Market Research



Pharma



Pharmacists



Physicians



Investigators &  
Study Coordinators



Payers



Service  
Providers



Patients

We are different from other market research companies in that we combine operational-level expertise with rigorous, industry-leading market research methodologies.

We deliver results and recommendations based on input from people who have been in the industry, owned P&Ls, developed strategies, and operationalized tactical plans.



# Library Subscription Plans

## Convenient, impactful data available to your entire organization

For over 15 years, we've been producing the highest quality, most relevant and actionable off-the-shelf market research in the pharmaceutical services industry. Producing ~25 report each year, we've built a substantial library of more than 240 syndicated market research reports.

### Our research categories include:



Clinical Trials



Manufacturing



Pharmaceutical Department Structures



Technology

### ✓ Unrestricted

We don't sell seats. Instantly obtain access for your entire organization—from your CEO to a first day employee.

### ✓ Distinctive

Receive novel insights from industry decision-makers on topics including: drug development / clinical trials, clinical and commercial manufacturing, clinical supplies and pharmaceutical outsourcing.

### ✓ Affordable

Receive access to all syndicated market research reports in our library, as well as those released during your subscription period. Our competitive library subscription pricing equates to the cost of a few individual report purchases.

# Custom Market Research

## Market research designed specifically for your company's needs

Our fit-for-purpose, custom market research helps answer your company's toughest questions. Whether you're looking to better understand your customers, markets, products, services, or employees, our experienced research analysts can design a study to meet your needs.

### Types of custom market research studies

- Brand Strength and Perception
- New Product / Service Development
- Message / Ad Testing
- Win / Loss Analysis
- Customer Satisfaction & Loyalty
- Customer Needs Assessment
- Thought Leadership

### Best-in-class access to industry decision-makers.



Pharmaceutical and biotech personnel



Patients



Contract drug development and manufacturing personnel



Prescribers



Clinical investigators and study coordinators



Pharmacists



Visit [isrreports.com](https://isrreports.com) to learn more